Type 2 diabetes mellitus (T2DM) contributes to a heightened risk of death, hepatic decompensation, and hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and cirrhosis, but the good news is that metformin may cut the risk of these adverse outcomes, a study has found.
Once-daily 14 mg oral semaglutide yields greater reduction in HbA1c and body weight than weekly 0.75 mg subcutaneous dulaglutide and is well tolerated in a Japanese population with uncontrolled type 2 diabetes (T2D), according to the PIONEER 10 study.
Older Singaporeans with limited English health literacy (EHL) are more likely to report uncertainty as regards taking medications correctly compared with those with adequate EHL, according to a study. Elderly people with limited EHL have difficulty understanding the information on prescription medication labels (PMLs), which then contributes to medication nonadherence.
Treatment with omalizumab, an anti-IgE monoclonal antibody, significantly improves outcomes in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), regardless of asthma status, based on a pooled analysis of the POLYP 1 and POLYP 2* studies presented at AAAAI 2020.
Combining the oral GnRH* receptor antagonist relugolix together with oestradiol and the progestin norethindrone helps protect against bone loss induced by oestrogen deprivation associated with the use of GnRH receptor antagonist monotherapy for treating heavy menstrual bleeding, according to the LIBERTY studies released during the ACOG 2020 Meeting.
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The COVID-19 pandemic has, and continues to have, a significant effect on the lives of individuals worldwide. Published reports suggest an elevated risk of COVID-19 among patients with cancer. As such, oncologists globally have had to adapt their management of cancer patients to minimize the risk of infection, while ensuring optimal care for this population.
The combination of atezolizumab and bevacizumab (atezo-bev) delivered better overall survival (OS) and progression-free survival (PFS) outcomes than sorafenib in patients with untreated, locally advanced metastatic or unresectable hepatocellular carcinoma (HCC), the phase III IMbrave150 trial has shown.
Current three-drug combination antiretroviral therapy (ART) regimens have proven to be highly effective, and the use of the relatively inexpensive rilpivirine (RPV) appears to have considerably better tolerability profile than efavirenz or protease inhibitors in regimens containing abacavir plus lamivudine (ABC/3TC) for treatment-naïve patients, offering a good, less costly approach to suppressing HIV, as shown in a Singapore study.
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.